Crohn's disease is an important cause of morbidity in Australia, with a prevalence of about 50 per 100 000 population. The disease is most common in adolescents and young adults, but can occur at any age. The cause is still unknown, but research towards finding the cause is proceeding apace, along with improvements in diagnosis and advances in therapy.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003; 124: 521-536.
- 2. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122: 854-866. <eMJA full text>
- 3. Chong AKH, Taylor ACF, Miller AM, Desmond PV. Initial experience with capsule endoscopy at a major referral hospital. Med J Aust 2003; 178: 537-540.
- 4. Fireman Z, Mahajna E, Broide E, et al. Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut 2003; 52: 390-392.
- 5. Hermon-Taylor J. Protagonist. Mycobacterium avium subspecies paratuberculosis is a cause of Crohn's disease. Gut 2001; 49: 755-756.
- 6. Quirke P. Antagonist. Mycobacterium avium subspecies paratuberculosis is a cause of Crohn's disease. Gut 2001; 49: 757-760.
- 7. Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 1093-1099.
- 8. Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
- 9. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405.
- 10. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549.
- 11. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
The author is a member of the Schering-Plough Crohn's Disease Advisory Board.